ISBN:  Unavailable

Category: Unavailable

Page count: 200

Objectives. Thrombolytic therapy results in improved survival of patients withacute myocardial infarction. Persisting problems of fibrinolysis - delayedreperfusion and reinfarctions - may be due to antifibrinolytic effect of plateletsć derived type 1 plasminogen- activator-inhibitor (PAI-1). Our study aims to study prospectively the relationship between the pre-treatment PAI-1 levels of patients with acute myocardial infarction and the outcome of thrombolysis with streptokinase, with the emphasis on reperfusion and reinfarction. Patients and methods. Included were 104 patients (78 males, 26 females, mean age 60,12 +- 11,0 years, range 33 to 81 years) with acute myocardial infarction (AMI), who fullfilled the criteria for high dose (1.500.000 IE), short-term (60 minutes) systemic intravenous infusion of streptokinase and to whome pre-treatment PAI-1 levels were estimated by chromogenic method (reference range 0,3 - 3,5 UžmL). The outcome of thrombolysis depended on reperfusion, determined by noninvasive reperfusion criteria and žor occurrence of reinfarctions. According to pre-treatment PAI-1levels, the patients were stratified to several groups, which were compared according to the outcome of thrombolysis, reperfusion and reinfarction. Besides PAI-1, before treatment age, gender, time to treatment, prior chronic diseases (arterial hypertension, diabetes, insulin therapy, prior myocardial infarction) were registrated and serum creatin kinase, total blood cell count and coagulation tests were estimated. (Abstract truncated at 2000 characters).